BioNTech SE (BNTX) has released an update.
BioNTech SE has released their unaudited interim condensed consolidated financial statements for the first half of 2024, highlighting key financial activities and results. The report showcases the company’s revenues, cost of sales, and research and development expenses, reflecting their ongoing commitment to innovation and growth in the biotechnology sector.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
